Patients
gastrointestinal motility
LYMPHOMA, ADVERSE EFFECTS, ONCOLOGY
Patients were eligible for the study if they met the following inclusion criteria: presence of a histologically or cytologically confirmed locally advanced or metastatic solid tumor, excluding lymphoma, for which standard therapy did not exist or had proven ineffective or intolerable; any prior palliative radiation must have been completed at least 7 days prior to the start of study treatment, and patients must have recovered from any acute adverse effects prior to the start of study treatment; Eastern Cooperative Oncology Group performance status of 0 or 1; no abnormalities in laboratory values within 7 days of initiation of study treatment; ≥ 18 years of age. Key exclusion criteria included: patients who were suffering from conditions that were likely to adversely affect gastrointestinal motility and/or transit or drug absorption; patients taking prescription medicines or foods known to interfere with the PKs of adavosertib or the probe cocktail drugs (see Supplementary Methods for restricted medications and additional exclusion criteria).